Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
RFXAP CRISPR/Cas9 KO Plasmid (h): sc-406793
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- RFXAP CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the RFXAP genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: RFXAP Antibody (RFXAD55A): sc-81368
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RFXAP CRISPR/Cas9 KO Plasmid (h) | sc-406793 | 20 µg | $397.00 |
Overview
RFXAP (regulatory factor X associated protein) is an essential cofactor of the RFX transcriptional complex that binds the X-box promoter element to drive expression of MHC class II genes. Through this role, RFXAP supports antigen processing and presentation and shapes adaptive immune activation by regulating CIITA-dependent transcriptional programs. Loss-of-function variants in RFXAP disrupt MHC class II expression and are associated with bare lymphocyte syndrome type II, characterized by impaired immune surveillance. In model systems, RFXAP perturbation impacts interferon-responsive pathways, immune cell differentiation, and mechanisms that govern host–pathogen interactions.
RFXAP CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RFXAP gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RFXAP together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RFXAP open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish RFXAP protein expression.
This CRISPR knockout system enables efficient generation of RFXAP-deficient cell models for investigation of RFXAP signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RFXAP exon(s) critical for RFXAP function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RFXAP genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by RFXAP CRISPR/Cas9 KO Plasmid (h) and RFXAP CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RFXAP locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by RFXAP HDR Plasmid (h) and RFXAP HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RFXAP homology arms to support homology-directed repair at defined RFXAP target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.